

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HighTide Therapeutics, Inc.

君圣泰医药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2511)

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGES IN COMPOSITION OF BOARD COMMITTEES

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of HighTide Therapeutics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Chen Mingyu (陳明宇) (“**Mr. Chen**”) has been appointed as an independent non-executive Director, the chairman of the audit committee of the Company (the “**Audit Committee**”) and a member of the remuneration committee of the Company (the “**Remuneration Committee**”) with effect from May 4, 2026.

The biographical of Mr. Chen is set out below:

Mr. Chen, aged 63, is currently the managing partner of D&E (Beijing) Business Consulting Co., Ltd., a finance, tax and business advisory service firm since 2019 and a visiting professor in the Executive Masters in Business Administration program at Tsinghua University since 2018. Mr. Chen has over 35 years of international experience in finance and taxation, including extensive hands-on involvement in financial reporting oversight, audit committee leadership, internal control evaluation, and risk management. His business expertise particularly focuses on providing financial and tax advisory services to Chinese enterprises expanding globally and operating overseas. His professional areas cover guiding cross-border merger and acquisition transactions, corporate valuation, personal wealth management, and designing and implementing global holding company structures for Chinese multinational companies, which combine tax optimization, financing, and capital repatriation strategies. From 1995 to 2018, Mr. Chen consecutively served as a partner in tax and business advisory at three leading global accounting firms: Deloitte, Ernst & Young, and KPMG, where he worked closely with audit teams on financial due diligence, reviewed the tax implications of complex financial statements, participated in assessing internal control frameworks for multinational clients, and gained practical experience in reviewing audit procedures related to cross-border transactions and evaluating compliance with applicable financial reporting standards (e.g., IFRS and HKFRS).

Mr. Chen currently serves as the chairman of the audit committee and an independent non-executive director of Yadea Group Holdings Ltd. (a company listed on the Hong Kong Stock Exchange, stock code: 1585) since June 16, 2023. He has also served as an independent non-executive director of China National Medicines Corporation Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600511) since April 7, 2022; G.H.Y Culture & Media Holding Co., Limited (a company listed on the Singapore Stock Exchange, stock code: XJB) since November 23, 2020; and Fujian Cosunter Pharmaceutical Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 300436) from January 6, 2021 to June 24, 2024.

Mr. Chen holds a Master of Business Administration from Fordham University in the United States, and has been a certified Chinese Tax Agent since 2000.

According to the letter of appointment between the Company and Mr. Chen, the term of office of Mr. Chen is three years commencing from May 4, 2026 and continue for a period of three years or until the third annual general meeting of the Company since the date of appointment, whichever is earlier, and shall be automatically renewed for successive periods of three years (subject always to re-election as and when required under the memorandum and articles of association of the Company) until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than one months' prior notice in writing. In accordance with the memorandum and articles of association of the Company, Mr. Chen will hold office until the next following annual general meeting of the Company and will be eligible for re-election. Mr. Chen is entitled to a remuneration of HKD200,000 per year, which has been recommended by the Remuneration Committee and approved by the Board with reference to (including but not limited to) his duties, responsibilities, performance, current market conditions and the remuneration benchmarks applicable to directors of listed companies of similar size and nature of the industry.

Save as disclosed above, as at the date of this announcement, Mr. Chen has confirmed that he (i) has no interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong); (ii) has no relationship with any Directors, senior management or substantial or controlling shareholders of the Company; and (iii) has not held any directorship in listed public companies in Hong Kong or overseas in the last three years preceding the date of his appointment; (iv) does not currently hold any other position with the Company or any of its subsidiaries; and (v) does not have any other information that is required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), nor is there any other matter that needs to be brought to the attention of the shareholders of the Company.

Mr. Chen has also confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) that he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence as at the date of this announcement.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Tan Bo (譚肇) (“**Mr. Tan**”) has resigned from his position as independent non-executive Director with effect from May 4, 2026 to devote more time to his other professional commitments. Mr. Tan has also ceased to be the chairman of the Audit Committee and a member of the Remuneration Committee with effect from the same day. Mr. Tan has confirmed that he had no disagreement with the Board and that there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to express its warmest welcome to Mr. Chen on his appointment and its gratitude to Mr. Tan for his long-term support and contribution during his tenure.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

Hong Kong, May 4, 2026

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Dr. LI Jin, Mr. HUNG Tak Wai and Mr. CHEN Mingyu as independent non-executive Directors.